Italian CMDO acquires manufacturing facility in India

P&R Group affiliate active pharmaceutical ingredients (API) contract development and manufacturing organization (CDMO) Olon has acquired a local generics chemical operations API manufacturing facility in Mahad, India, as part of a continuing expansion of its global footprint.

Paolo Tubertini, chief executive of Milan, Italy-based of Olon, commented: "By acquiring a manufacturing base in India, Olon will have the opportunity to accelerate growth by adding new CDMO projects and to develop new generic products for the Indian market. It comes with a world-class manufacturing facility and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements.

Following the acquisition of Ricerca Biosciences' Chemical Division in mid-2017 and the investment of more than 10 million euros to expand APIs manufacturing lines in the Settimo Torinese facility − a leading-edge plant for development and production of APIs and advanced intermediates through microbial fermentation technology − we have now completed a further step in our strategic plan. To accomplish all the objectives listed in the Olon 3 years' development plan, we will move to the next target: to play an important role in the manufacturing of biologics API's."